

## **Details of Independent Directors' Familiarization Program for the financial year 2016-2017**

Sun Pharmaceutical Industries limited ("the Company") has put in place a system to familiarize its independent directors about the Company, its products, the Industry and business model of the Company. In addition, it also undertakes various measures to update the independent directors about the ongoing events and development relating to the Company.

All the independent directors of the Company are made aware of their role, responsibilities & liabilities at the time of their appointment, reappointment, through a formal letter of appointment, which also stipulates various terms and conditions of their appointment/re-appointment.

As per regulation 25(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the following Familiarization sessions were held at Board /Committee Meeting during the financial year ended 31st March 2017:

Date of Session/Program	Area Covered
14.05.2016	- Presentation on Internal control processes of the Company highlighting the key issues faced therein including internal Audit plan for 15-16
	- Presentation on Internal Audit Plan for 16-17
	- Presentation on Risk Management framework
	- Presentation on Whistle Blower policy of the Company and review of the nature of complaints received including the process of investigation
	- Regulatory update and discussion on Indian Accounting Standards (IND-AS)
30.05.2016	- Presentation on Internal Audit process and Internal Financial Controls conducted by the Auditors of the Company highlighting on operational and fraud prevention controls, deficiencies and remediation
	- Status update on the various business opportunities and various acquisition proposals in USA, Europe and various other markets
	- Presentation on Annual operating and capital plans and Budget for the financial year 2016-2017
	- Presentation on Consent Decree Process
	- Regulatory updates

12.08.2016	- Presentation on Internal control processes of the Company highlighting the key issues faced therein
	- Status update on the various business opportunities and various acquisition proposals in USA, Europe and various other markets
	- Presentation on Forex Risk Management policy
	- Presentation on API Business of the Company on overall business performance
15 00 001 5	- Regulatory updates
17.09.2016	- Presentation on working of R & D Department of the Company
10.11.2016	- Presentation on Internal control processes of the Company highlighting the key issues faced therein
	- Presentation on Internal Financial Control Framework
	- Presentation on Risk Mitigation plans of the Company
	- Status update on various acquisition proposals in USA –Europe and various other markets, considered by the Company
13.02.2017	- Presentation on CSR activities
14.02.2017	- Presentation on Internal control processes of the Company highlighting the key issues faced therein
	- Status update on various acquisition proposals in USA –Europe and various other markets, considered by the Company
	- Regulatory updates
	- Presentation on organization health index survey finding and analysis



Details of attendance of Independent Directors in Familiarization sessions are as follows:

S.No	Name of the Independent						Cumulative (from 1 <sup>st</sup> April, 2015)			
	Director	Held		Attended		Held		Attended		
		No. of Sessions	Duration (in hours) (approx.)	No. of Sessions	Duration (in hours) (approx.)	No. of Sessions	Duration (in hours) (approx.)	No. of Sessions	Duration (in hours) (approx.)	
1.	Mr. S. Mohanchand Dadha	10	6.40	9	5.10	15	15.10	14	13.40	
2.	Mr. Hasmukh S. Shah	10	6.40	8	3.35	15	15.10	13	12.05	
3.	Ms. Rekha Sethi	6	3.10	6	3.10	11	11.40	11	11.40	
4.	Mr. Keki Mistry	10	6.40	9	6.20	15	15.10	13	12.50	
5.	Mr. Ashwin Dani	10	6.40	7	4.40	15	15.10	11	10.10	